Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ENERGY Study
NCT05734196Phase 1Terminated
- Sponsor
- Inozyme Pharma
- Start
- Jun 2023
- Primary completion
- Sep 2026
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of INZ-701 in ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency and pseudoxanthoma elasticum (PXE), sponsored by Inozyme Pharma. Primary endpoints: Number of Treatment Emergent Adverse Events at 52 weeks, Incidence of Anti-Drug Antibodies at 52 weeks and 1 more. Started Jun 2023; status: terminated.
02
Drugs
INZ-701
03
Conditions
ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiencypseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on NCT05734196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734196.